Stock Analysis
PTC Therapeutics, Inc. (PTCT) Stock Analysis
PTC Therapeutics, Inc. (PTCT) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
PTC Therapeutics, Inc. (PTCT) currently has an AIQ Score of 53/100, indicating a neutral setup. Quality is the strongest factor at 82/100. Momentum is the weakest current factor at 33/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
PTCT at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $69.30 |
| AIQ Score | 53/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Sell |
| Market Cap | $5.89B |
| P/E Ratio | -30.28 |
| Forward P/E | — |
| EPS | $1.01 |
| Revenue TTM | $360.52M |
| Dividend Yield | 0.00% |
| Beta | 0.55 |
| Volume | 673.54K |
| 52-week range | $55.14-$90.87 |
| RSI 14 | 39.75 |
| 50-Day SMA | $75.82 |
| 200-Day SMA | $73.35 |
| Analyst Price Target | $104.78 |
| Next Earnings | Nov 3, 2026 |
PTCT
OverviewPTCT Stock Analysis Summary
PTC Therapeutics, Inc. (PTCT) currently has an AIQ Score of 53/100, indicating a neutral setup. Quality is the strongest factor at 82/100. Momentum is the weakest current factor at 33/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, PTCT has AIQ Score of 53/100 with Quality base of 82/100 and fading Momentum at 33/100. Wait for component alignment before adding exposure.
Quality (82/100) leads while Momentum (33/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -2.94% stock move · PTCT classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is PTCT Bullish or Bearish Right Now?
PTCT currently has a neutral overall setup. Quality is the strongest factor at 82/100, while Momentum is weakest at 33/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Quality is supportive at 82/100.
- - Risk Resilience is supportive at 61/100.
- - Analyst target implies +51.20% upside from the latest quote.
- - Value is the current constraint at 38/100.
- - Momentum is weak at 33/100.
- - Price is -5.52% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (32 vs 7).
Current Consensus
PTCT's Technical Analysis Consensus is currently Strong Sell, with 7 buy, 6 neutral, and 32 sell votes. PTCT's 14-day RSI is 39.75, which places the stock in a weaker momentum range. PTCT's beta is 0.55, indicating lower market sensitivity than the broad market.
What Changed in PTCT?
Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.
What Would Change the PTCT Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
PTCT Decision Framework
Public evidence layers, setup checks, and risk context for PTC Therapeutics, Inc..
PTC Therapeutics, Inc. (PTCT) Stock Analysis
PTC Therapeutics, Inc. has an AIQ Score of 53/100 in a Neutral regime. Quality is strongest at 82/100. Beta is 0.55, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | PTCT is in a Neutral AIQ regime with score 53/100. |
| Signal Conflict | The primary conflict is that quality leads at 82/100 while momentum lags at 33/100. |
| Factor Evidence | Momentum 33/100 · Value 38/100 · Quality 82/100 · Risk 61/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 82/100.
Momentum is 33/100 and RSI (14) is 39.7.
PTCT is in a Neutral regime at 53/100.
Risk factor is 61/100 with beta 0.55 and annual volatility 40.39%.
Current conflict: quality leads at 82/100 while momentum lags at 33/100.
PTCT Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
PTCT Fundamentals
PTCT valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
PTCT Technical Analysis
PTCT technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
PTCT Stock Catalysts
Track PTCT earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
PTCT Dividend Analysis
PTCT dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
PTCT Financial Data
PTCT revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
PTCT Risk Analysis
PTCT volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
PTCT Stock News
PTCT stock news, market tone, recent headlines, and catalyst context.
PTCT vs Life Sciences / Tools / CRO Peers
Current peer cohort: PTCT · RVTY · TECH · TMO · TXG. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| PTCT Current stock | 53/100 | 38/100 | 33/100 | 61/100 | 0.55 | 40.39% | Current |
| RVTY Revvity | 57/100 | 42/100 | 81/100 | 64/100 | 1.2 | 37.79% | PTCT vs RVTY |
| TECH Bio-Techne | 56/100 | 26/100 | 62/100 | 89/100 | 0.82 | 46.71% | PTCT vs TECH |
| TMO Thermo Fisher Scientific | 51/100 | 39/100 | 60/100 | 62/100 | 0.77 | 30.64% | PTCT vs TMO |
| TXG 10x Genomics | 50/100 | 34/100 | 67/100 | 38/100 | 2.42 | 72.52% | PTCT vs TXG |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 4, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Sep 5, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching PTCT
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for PTCT
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
PTCT Stock FAQ
What is PTCT stock price today?
PTC Therapeutics, Inc.'s current stock price is $69.30. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is PTCT bullish or bearish right now?
PTCT's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is PTCT's market cap?
PTCT's market cap is $5.89B based on the latest completed market-close snapshot from Sep 4, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is PTCT's current P/E ratio?
PTCT's current P/E ratio is -30.28 based on the latest completed market-close snapshot from Sep 4, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is PTCT's RSI?
PTCT's 14-day RSI is 39.75 based on the latest completed market-close snapshot from Sep 4, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is PTCT above its 50-day and 200-day moving averages?
PTCT is -8.60% from its 50-day SMA and -5.52% from its 200-day SMA based on the latest completed market-close snapshot from Sep 4, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is PTCT's next earnings date?
PTCT's next earnings date is currently listed as Nov 3, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does PTCT pay a dividend?
PTCT's dividend yield is 0.00% based on the latest completed market-close snapshot from Sep 4, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.